Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
PHILADELPHIA—Carr Douglas, Senior Vice President of Finance & Operations at Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 351 shares of the company’s common stock. The shares were sold at a price of $0.78 each, amounting to a total transaction value of $273. Following this sale, Douglas retains ownership of 316,796 shares in the company.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units. According to the filing, these sales were automatic and not at the discretion of Douglas. Want deeper insights into Century Therapeutics’ financial health and valuation? InvestingPro offers exclusive analysis and over 30 additional financial metrics not available to regular investors.
In other recent news, Century Therapeutics has reported significant developments in its operations. The company is set to launch a Phase 1/2 trial of its investigational cell therapy CNTY-101, in partnership with Friedrich-Alexander University Erlangen-Nürnberg. This trial, named CARAMEL, aims to evaluate the therapy’s potential in treating B-cell mediated autoimmune diseases.
Additionally, Century Therapeutics’ collaboration with Bristol-Myers Squibb (NYSE:BMY) has been terminated. The collaboration was initially aimed at researching and developing novel therapies for hematologic malignancies. Despite this change, Century Therapeutics plans to continue exploring opportunities related to acute myeloid leukemia and multiple myeloma.
In the realm of financial analysis, Piper Sandler has adjusted its price target for Century Therapeutics, maintaining an Overweight rating despite a significant reduction to $4 from the previous $12. On the other hand, Clear Street initiated coverage on Century Therapeutics with a Buy rating and a price target of $9.00, indicating a positive outlook on the company’s future performance.
These are the latest developments in the operations and financial analysis of Century Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.